Mouse Anti-PBLD Recombinant Antibody (CBFYM-3049) (CBMAB-M3245-FY)

Han, L., Lin, X., Yan, Q., Gu, C., Li, M., Pan, L., ... & Li, A. (2022). PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells. Oncogene, 41(13), 1851-1865.

Chen, S., Liu, H., Li, Z., Tang, J., Huang, B., Zhi, F., & Zhao, X. (2021). Epithelial PBLD attenuates intestinal inflammatory response and improves intestinal barrier function by inhibiting NF-κB signaling. Cell Death & Disease, 12(6), 563.

Zhu, M., Wang, F., Mi, H., Li, L., Wang, J., Han, M., & Gu, Y. (2020). Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells. Cell Cycle, 19(23), 3277-3288.

Liang, Y., Song, X., Li, Y., Su, P., Han, D., Ma, T., ... & Yang, Q. (2019). circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer. Oncogene, 38(42), 6850-6866.

Wu, J., Niu, Q., Yuan, J., Xu, X., & Cao, L. (2019). Novel compound cedrelone inhibits hepatocellular carcinoma progression via PBLD and Ras/Rap1. Experimental and Therapeutic Medicine, 18(6), 4209-4220.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols